Anavex Life Sciences' (AVXL) stock surged on new Alzheimer's trial data, but data's inconsistency raises concerns, making the ...

After dosing with Cognition’s CT1812, study reports declines of 95% and higher in subgroup with below-median p-tau217.

Roughly 82 percent of Americans support requiring Medicare and insurance companies to cover the Alzheimer's treatments.

This year has seen several biopharma companies drop Alzheimer’s and Parkinson’s disease programs, but experts say plenty are ...

Shares of Disc Medicine Inc. (NASDAQ:IRON) were trading at $56.94, up $9.81, or 20%, after the firm disclosed positive feedback from its end-of-phase II meeting with the FDA, supporting the regulatory ...

The Alzheimer's disease drug Kisunla will face major reimbursement challenges in the U.K. after the cost-effectiveness ...

Biogen's Q3 earnings report shows flat growth but highlights its value for risk-tolerant investors in CNS disease treatment.

Based on early, interim data, Lexeo is already positioning its gene therapy as a potentially safer alternative than available anti-amyloid drugs.

FILE - R. Scott Turner, Professor of Neurology and Director of the Memory Disorder Center at Georgetown University Hospital, points to PET scan results that are part of a study on Alzheimer's ...

People with schizophrenia often experience auditory hallucinations of voices that berate and bully them. New data suggests they may benefit from a type of behavioral therapy that uses digital avatars ...

ARIA-E was observed in 14 percent of patients who received a modified dosing regimen, compared to 24 percent of patients who received standard dosing.

A modified dosing regimen with Eli Lilly’s Alzheimer’s drug Kisunla (donanemab) has shown a reduction in amyloid-related ...